Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 p ...

Meanwhile, Lilly and Innovent are running upwards of 20 studies as they play catch-up with other PD-1/PD-L1 drugs testing the drug in other indications, including kidney, liver, colorectal ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Key stocks recommended by Jefferies for 2025 include Mankind Pharma, JB Chemicals, and Sun Pharmaceutical Industries.